Evaluating bone grafting techniques for dental implants
Efficacy of Xenograft Alone or Mixed With Arginyl-Glycyl-Aspartic Acid (RGD) in Horizontal Ridge Augmentation With Split-crest Technique for Implant Placement. A Randomized Clinical Trial
This study is testing whether using a special substance mixed with a bone graft helps people getting dental implants have better results than using the bone graft alone.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 18 (estimated) |
| Ages | 18 Years to 30 Years |
| Sex | All |
| Sponsor | Al-Azhar University Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Cairo, Nasr City) |
| Trial ID | NCT06585852 on ClinicalTrials.gov |
What this trial studies
This study compares the effectiveness of using a xenograft alone versus a xenograft mixed with Arginylglycylaspartic acid (RGD) in a horizontal ridge augmentation procedure for dental implant placement. Participants will be divided into two groups: one receiving the xenograft alone and the other receiving the xenograft mixed with RGD, both undergoing a surgical ridge splitting procedure. Follow-up assessments will occur at 1 and 3 months post-implant placement to evaluate outcomes.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18-30 with insufficient bone width for dental implants and good oral hygiene.
Not a fit: Patients who are heavy smokers, undergoing immunosuppressive therapy, or pregnant may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve the success rates of dental implants in patients with insufficient bone width.
How similar studies have performed: Previous studies have shown promising results with similar grafting techniques, but this specific combination of xenograft and RGD is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Adults (age 18-30) exhibiting initial insufficiently bone width. 2. Patients with good oral hygiene. 3. Patients must be free from systemic diseases that may influence the outcome of the therapy. 4. Patients with bony horizontal defects alone, Class III \& IV. Exclusion Criteria: 1. Heavy smokers. 2. Patient treated by immunosuppressive chemotherapy or radio therapy, 3. Allergy to any material or medication used in the study. 4. Pregnant females.
Where this trial is running
Cairo, Nasr City
- Al Azhar University of Cairo — Cairo, Nasr City, Egypt (Recruiting)
Study contacts
- Study coordinator: Mahmoud Taha, PHD
- Email: info@azhar.edu.eg
- Phone: 01225864104
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.